No beneficial effects of amantadine in treatment of chronic hepatitis C patients

Digestive and Liver Disease

Volumn 42, Issue 7, 2010, Pages 496-502

  van Soest, Hanneke ^a   van der Schaar, Peter J ^b   Koek, Ger H ^c   de Vries, Richard A ^d   van Ooteghem, Nancy A ^e   van Hoek, Bart ^f   Drenth, Joost P H ^g   Vrolijk, Jan M ^h   Lieverse, Rob J ⁱ   Houben, Peter ^j   van der Sluys Veer, Annet ^k   Siersema, Peter D ^a   Schipper, Marguerite E I ^a   van Erpecum, Karel J ^a   Boland, Greet J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ GELRE HOSPITALS   (Netherlands)

^j Ziekenhuis Zeeuws Vlaanderen   (Netherlands)

^k Onze Lieve Vrouwe Gasthuis Amsterdam ^*  (Netherlands)

more..

Author keywords

Amantadine; Hepatitis C; PEG interferon; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; AMANTADINE; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; RIBAVIRIN; VIRUS RNA;

ADULT; AGRANULOCYTOSIS; ANEMIA; ANOREXIA; ARTICLE; CATATONIA; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; GENOTYPE; HEALTH CARE POLICY; HEPATITIS C; HUMAN; INNER EAR DISEASE; IRRITABILITY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; PANCREATITIS; PERIANAL ABSCESS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETINA VEIN OCCLUSION; RHABDOMYOLYSIS; SIDE EFFECT; SLEEP DISORDER; THROMBOCYTOPENIA; THYROID DISEASE; TOXIC HEPATITIS; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AMANTADINE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTENTION TO TREAT ANALYSIS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; VIRAL LOAD;

EID: 77955554384     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.10.006     Document Type: Article

References (28)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562.
2. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
3. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
4. Dolin R., Reichman R.C., Madore H.P., et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982, 307:580-584.
5. Koff W.C., Elm J.L., Halstead S.B. Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrob Agents Chemother 1980, 18:125-129.
6. Reuman P.D., Bernstein D.I., Keefer M.C., et al. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res 1989, 11:27-40.
7. Van Voris L.P., Betts R.F., Hayden F.G., et al. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. J Am Med Assoc 1981, 245:1128-1131.
8. Tabone M., Ercole E., Zaffino C., et al. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol 1998, 30:611-613.
9. Caronia S., Bassendine M.F., Barry R., et al. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study. J Hepatol 2001, 35:512-516.
10. Mangia A., Leandro G., Helbling B., et al. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol 2004, 40:478-483.
11. Brillanti S., Foli M., Di T.M., et al. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol 1999, 31:130-134.
12. Smith J.P. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997, 42:1681-1687.
13. Berg T., Kronenberger B., Hinrichsen H., et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 2003, 37:1359-1367.
14. Helbling B., Stamenic I., Viani F., et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 2002, 35:447-454.
15. Mangia A., Minerva N., Annese M., et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001, 33:989-993.
16. Tabone M., Laudi C., Delmastro B., et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol 2001, 35:517-521.
17. Steinmann E., Whitfield T., Kallis S., et al. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007, 46:330-338.
18. Dienstag J.L., McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006, 130:231-264.
19. Mangia A., Ricci G.L., Persico M., et al. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs. interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005, 12:292-299.
20. Angelico M., Koehler-Horst B., Piccolo P., et al. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naive patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2008, 20:680-687.
21. von Wagner M., Hofman P., Teuber G., et al. Randomized, double-blind, placebo-controlled trial of Peginterferon alfa-2a (40kD) and ribavirin with and without 400mg amantadine-sulphate for 48 weeks in treatment naive HCV genotype 1-infected patients. Hepatology 2007, 46:S1342.
22. Deltenre P., Henrion J., Canva V., et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 2004, 41:462-473.
23. Teuber G., Pascu M., Berg T., et al. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol 2003, 39:606-613.
24. Zeuzem S. Induction therapy in chronic hepatitis C: deja-vu with pegylated interferons?. J Hepatol 2004, 41:488-490.
25. Dixit N.M., Layden-Almer J.E., Layden T.J., et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922-924.
26. Lindsay K.L., Trepo C., Heintges T., et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001, 34:395-403.
27. Silva I.S., Ferraz M.L., Perez R.M., et al. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2004, 19:314-318.
28. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.